ClinicalTrials.gg
RecruitingNCT06333587MIPA-MITTUpdated Mar 27, 2024

Minimally Invasive Treatments of the Thyroid

An observational study in Papillary Thyroid Microcarcinoma, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by European Institute of Oncology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)

Read the detailed description

Image-guided thermal ablations have been successfully applied in the treatment of several type of tumors, and have been recently proposed as a potential alternative to surgery also in patients with thyroid diseases, and named "Minimally Invasive Treatments of the Thyroid (MITT)". These minimally invasive treatments, compared to surgical treatment have similar efficacy, fewer complications, better quality of life, and better cosmetic outcomes. These procedures allow precise delivery of the heat locally to the lesion, sparing the surrounding thyroid tissue, and thus minimizing the invasiveness of the treatment and the impact on thyroid function.

This study aim to establish a prospective registry of the cases of patients treated with MITT for a Papillary Thyroid MicroCarcinoma (PTMC), in order to validate the safety of the procedure and to set the basis for collecting long term results in a large cohort of patients.

02

Conditions studied

  • Papillary Thyroid Microcarcinoma
03

In context

Papillary Thyroid Microcarcinoma

24 studies on the registry are indexed under Papillary Thyroid Microcarcinoma; 8 are open to participants now.

This study's planned enrollment of 270 is below the median of 480 across 15 observational studies indexed under Papillary Thyroid Microcarcinoma.

Browse Papillary Thyroid Microcarcinoma studies →

Lead sponsor

European Institute of Oncology is the lead sponsor of 186 studies on the registry; 118 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with thyroid diseases suitable for "Minimally Invasive Treatments of the Thyroid (MITT)" as potential alternative to surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 18years
  • Patients with diagnosis of papillary thyroid microcarcinoma, citologically proven, suitable for MITT.
  • Written must be signed and dated by the patient and the investigator prior to inclusion.
  • Patients must be accessible for follow-up

Exclusion criteria

Exclusion Criteria:

  • Tumors > 1 cm, other citological type, refusal of MITT, unsuitable for MITT, unmanageable coagulative disorders
  • Patients with psychiatric, addictive, or any disorder, which compromises ability to give for participation in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No

Groups and cohorts

  • image-guided thermal ablation

    image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma

    Procedure: image-guided thermal ablation

Interventions

  • Procedureimage-guided thermal ablation

    image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma

06

What researchers measure

Primary outcomes

  1. The proportion of patients with major complications occurring within one month after the date of intervention

    Complications will be reported according to modified Society of Interventional Radiology (SIR) classification

    Time frame: 1 month

Secondary outcomes

  1. Percentage of patients with local recurrence at 10 years

    Evaluation of disease free survival (DFS): percentage of patient whith a local recurrence at 10 years of follow up

    Time frame: 10 years

  2. Percentage of patients with distant metastasis at 10 years

    Evaluation of disease free survival (DFS): percentage of patient whith distant metastasis at 10 years of follow up

    Time frame: 10 years

  3. Percentage of patients died at 10 years

    Evaluation of Overall Survival (OS): Percentage of patients died at 10 years

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 27, 2024
StartActual
Oct 10, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2035
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06333587
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Oct 10, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Mar 27, 2024

Study contacts

Giovanni Mauri
Contact
giovanni.mauri@ieo.it
+390294372691
Giovanni Mauri
principal investigator · European Institute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion